Bisnordihydrotoxiferine

Bisnordihydrotoxiferine

SCHEMBL29525342

C/C=C1/CN2CCC34c5ccccc5N5/C=C6/C7CC8N(CCC89c8ccccc8N(/C=C(/C1CC23)C54)C69)C/C7=C/C

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 6/20 0.56
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
CHRM2 P08172 2/20 0.43
CHRNA4 P43681 1/20 0.43
KCNH2 Q12809 1/20 0.43
HTR3A P46098 1/20 0.39
OPRM1 P35372 3/20 0.36
OPRK1 P41145 3/20 0.36
OPRD1 P41143 1/20 0.36
CYP3A4 P08684 2/20 0.36
GLRA1 P23415 2/20 0.36
GLRB P48167 2/20 0.36
SCN1A P35498 1/20 0.36
TAS2R46 P59540 1/20 0.36
SCN2A Q99250 1/20 0.36
SCN3A Q9NY46 1/20 0.36
TAS2R10 Q9NYW0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29352385 0.86 CHRNA7 (0.44) CHRNA7MEN1KMT2ATDP1CHRM2
Isostrychnine SCHEMBL29898321 0.68 CHRNA7 (0.43) CHRNA7MEN1KMT2ACHRM2CHRNA4
Hydrochloric Acid SCHEMBL31650965 0.64 CHRNA7 (1.00) CHRNA7CHRM2CHRNA4KCNH2HTR3A
Vinervine SCHEMBL30046744 0.62 MEN1 (0.74) MEN1KMT2ATDP1OPRM1OPRK1
SCHEMBL31150554 0.62 MEN1 (1.00) MEN1KMT2ATDP1OPRM1OPRK1
Alcuronium SCHEMBL30817419 0.60 CHRNA7 (0.98) CHRNA7CHRM2CHRNA4KCNH2HTR3A
Akuammicine SCHEMBL29517606 0.59 MEN1 (0.69) MEN1KMT2ATDP1OPRM1OPRK1
SCHEMBL8053306 0.48 OPRL1 (0.61) OPRM1OPRK1OPRD1
SCHEMBL6334445 0.46 NOTUM (0.42) MEN1KMT2AOPRM1OPRK1OPRD1
SCHEMBL13068280 0.46 AKT1 (0.49) OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111447-A1 TREATMENT OF CANCER WITH DRUG COMBINATIONS FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) 2025-05-30 WO claimed
US-20240180891-A1 SYNERGISTIC MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR INDUCING WEIGHT LOSS AND THE TREATMENT OF DIABETIC PATHOLOGIES BUCK INSTITUTE FOR RESEARCH ON AGING (US) 2024-06-06 US claimed
CN-115448969-A Refining method of desogestrel 上海格苓凯生物科技有限公司 2022-12-09 CN claimed
WO-2022140279-A1 SYNERGISTIC MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR INDUCING WEIGHT LOSS AND THE TREATMENT OF DIABETIC PATHOLOGIES BUCK INSTITUTE FOR RESEARCH ON AGING (US) 2022-06-30 WO claimed
CN-113599402-B Semen Platycladi or semen Platycladi extract and application thereof 中国科学院上海药物研究所 2022-06-28 CN claimed
US-20260068922-A1 LIQUID COMPOSITION FOR AN ELECTRONIC VAPOR DEVICE CRONOS GROUP INC (US) 2026-03-12 US disclosed
US-20250376488-A1 FARNESOID X RECEPTOR MODULATORS INTERCEPT PHARMACEUTICALS INC (US) 2025-12-11 US disclosed
US-20250283122-A1 BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS GINKGO BIOWORKS, INC. (US) 2025-09-11 US disclosed
US-12379386-B2 Antibodies to 25-hydroxyvitamin D2 and D3 for detecting total 25-hydroxyvitamin D SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2025-08-05 US disclosed
US-20250207142-A1 BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS GINKGO BIOWORKS, INC. (US) 2025-06-26 US disclosed
WO-2025111447-A1 TREATMENT OF CANCER WITH DRUG COMBINATIONS FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) 2025-05-30 WO disclosed
US-20250145659-A1 SYNTHESIS OF CHOLESTEROL FORM BISNORALCOHOL FERMENTA BIOTECH LIMITED (IN) 2025-05-08 US disclosed
CN-113599402-B Semen Platycladi or semen Platycladi extract and application thereof 中国科学院上海药物研究所 2022-06-28 CN disclosed
US-20220195472-A1 BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS GINKGO BIOWORKS, INC. (US) 2022-06-23 US disclosed
US-11345721-B2 TGR5 modulators and methods of use thereof INTERCEPT PHARMACEUTICALS, INC. (US) 2022-05-31 US disclosed
US-20220151948-A1 Treating Vasculature Related Diseases or Disorders Using Nanoparticles THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-05-19 US disclosed
WO-2022074965-A1 FILAMENT, MATERIAL, AND MATERIAL MANUFACTURING METHOD 三菱瓦斯化学株式会社 2022-04-14 WO disclosed
EP-3981779-A1 FARNESOID X RECEPTOR MODULATORS Intercept Pharmaceuticals, Inc. (US) 2022-04-13 EP disclosed
US-11274320-B2 Biosynthesis of cannabinoids and cannabinoid precursors GINKGO BIOWORKS, INC. (US) 2022-03-15 US disclosed
US-11241394-B2 Treating vasculature related diseases or disorders using nanoparticles THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12379386-B2 Antibodies to 25-hydroxyvitamin D2 and D3 for detecting total 25-hydroxyvitamin D VDR, GC, CYP24A1 CHRNA7 4387/4885MEN1 1998/4885KMT2A 4123/4885
US-11345721-B2 TGR5 modulators and methods of use thereof GPBAR1, TAAR5, LPAR5 CHRNA7 3363/4885MEN1 3310/4885KMT2A 3147/4885
US-20260068922-A1 LIQUID COMPOSITION FOR AN ELECTRONIC VAPOR DEVICE CNR2, CNR1, TRPV1 CHRNA7 207/4885MEN1 4191/4885KMT2A 2722/4885
US-20240180891-A1 SYNERGISTIC MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR INDUCING WEIGHT LOSS AND THE TREATMENT OF DIABETIC PATHOLOGIES PDXK, PLPBP, GLS CHRNA7 2462/4885MEN1 3773/4885KMT2A 1599/4885
US-20250145659-A1 SYNTHESIS OF CHOLESTEROL FORM BISNORALCOHOL HMGCR, DHCR7, CYP46A1 CHRNA7 350/4885MEN1 2116/4885KMT2A 2805/4885
US-20250376488-A1 FARNESOID X RECEPTOR MODULATORS NR1H4, SLC10A1, GPBAR1 CHRNA7 1030/4885MEN1 1113/4885KMT2A 4219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.